How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study.
Botulinum toxin
Cervical dystonia
Observational study
Satisfaction
Treatment
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
25
07
2019
accepted:
03
09
2019
revised:
02
09
2019
pubmed:
11
9
2019
medline:
15
4
2020
entrez:
11
9
2019
Statut:
ppublish
Résumé
Patients with cervical dystonia (CD) typically require regular injections of botulinum toxin to maintain symptomatic control. We aimed to document long-term patient satisfaction with CD symptom control in a large cohort of patients treated in routine practice. This was a prospective, international, observational study (NCT01753349) following the course of adult CD treated with botulinum neurotoxin type A (BoNT-A) over 3 years. A comprehensive clinical assessment status was performed at each injection visit and subjects reported satisfaction in two ways: satisfaction with symptom control at peak effect and at the end of treatment cycle. Subject satisfaction remained relatively stable from the first to the last injection visit. At 3 years, 89.9% of subjects reported satisfaction with symptom control at peak effect and 55.6% reported satisfaction with symptom control at end of treatment cycle. By contrast, objective ratings of CD severity showed an overall reduction over 3 years. Mean ± SD Toronto Western Spasmodic Rating Scale (TWSTRS) Total scores (clinician assessed at end of treatment cycle) decreased from 31.59 ± 13.04 at baseline to 24.49 ± 12.43 at 3 years (mean ± SD reduction from baseline of - 6.97 ± 11.56 points). Tsui scale scores also showed gradual improvement; the percent of subjects with a tremor component score of 4 reduced from 12.4% at baseline to 8.1% at 3 years. Despite objective clinical improvements over 3 years, subject satisfaction with symptom control remained relatively constant, indicating that factors other than symptom control also play a role in patient satisfaction.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with cervical dystonia (CD) typically require regular injections of botulinum toxin to maintain symptomatic control. We aimed to document long-term patient satisfaction with CD symptom control in a large cohort of patients treated in routine practice.
METHODS
METHODS
This was a prospective, international, observational study (NCT01753349) following the course of adult CD treated with botulinum neurotoxin type A (BoNT-A) over 3 years. A comprehensive clinical assessment status was performed at each injection visit and subjects reported satisfaction in two ways: satisfaction with symptom control at peak effect and at the end of treatment cycle.
RESULTS
RESULTS
Subject satisfaction remained relatively stable from the first to the last injection visit. At 3 years, 89.9% of subjects reported satisfaction with symptom control at peak effect and 55.6% reported satisfaction with symptom control at end of treatment cycle. By contrast, objective ratings of CD severity showed an overall reduction over 3 years. Mean ± SD Toronto Western Spasmodic Rating Scale (TWSTRS) Total scores (clinician assessed at end of treatment cycle) decreased from 31.59 ± 13.04 at baseline to 24.49 ± 12.43 at 3 years (mean ± SD reduction from baseline of - 6.97 ± 11.56 points). Tsui scale scores also showed gradual improvement; the percent of subjects with a tremor component score of 4 reduced from 12.4% at baseline to 8.1% at 3 years.
CONCLUSIONS
CONCLUSIONS
Despite objective clinical improvements over 3 years, subject satisfaction with symptom control remained relatively constant, indicating that factors other than symptom control also play a role in patient satisfaction.
Identifiants
pubmed: 31501975
doi: 10.1007/s00415-019-09527-2
pii: 10.1007/s00415-019-09527-2
pmc: PMC6851034
doi:
Substances chimiques
Neuromuscular Agents
0
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3038-3046Investigateurs
A Abdulnayef
(A)
N U Adatepe
(NU)
M A Araujo Leite
(MA)
S Badarny
(S)
O Bajenaru
(O)
M Bares
(M)
P Bejjani
(P)
B Bergmans
(B)
R Bhidayasiri
(R)
H Bozic
(H)
F E Cardoso Costa
(FE)
C Carlstrom
(C)
G Castelnovo
(G)
M H Chang
(MH)
Y Y Chang
(YY)
T M Chung
(TM)
M Coletti-Moja
(M)
V Delvaux
(V)
P Dioszhegy
(P)
O Dogu
(O)
W Duzynski
(W)
E Ehler
(E)
L Espinosa Sierra
(L)
G Fabbrini
(G)
J Ferreira
(J)
A Ferreira Valadas
(A)
C Foresti
(C)
P Girlanda
(P)
K J Goh
(KJ)
A Graca Velon
(A)
S Grill
(S)
T Gurevitch
(T)
M Hadidi
(M)
M A Hamimed
(MA)
A Hamri
(A)
T Harrower
(T)
S Hassin
(S)
P Hedera
(P)
J F J G Hernandez
(JFJG)
J Hernandez Franco
(J)
B Ho
(B)
S L Ho
(SL)
A Hughes
(A)
T Ilic
(T)
J S Inshasi
(JS)
C W Ip
(CW)
S Jamieson
(S)
R D G Jamora
(RDG)
R Jech
(R)
B S Jeon
(BS)
A Kaminska
(A)
M Karpova
(M)
D Khasanova
(D)
J M Kim
(JM)
J W Kim
(JW)
C Y Kok
(CY)
A Korenko
(A)
J Korv
(J)
S Koussa
(S)
T Kovacs
(T)
A Kreisler
(A)
P Krystkowiak
(P)
W Kumthornthip
(W)
C H Lin
(CH)
F Lundin
(F)
G Lus
(G)
M Magalhaes
(M)
A N Masmoudi
(AN)
R Mercelis
(R)
A Misbahuddin
(A)
C Moebius
(C)
B Mohammadi
(B)
B Nazem
(B)
K Ng
(K)
G Nurlu
(G)
J Nyberg
(J)
D Nyholm
(D)
S Ochudlo
(S)
P Otruba
(P)
R Pfister
(R)
Z Pirtosek
(Z)
D Pokhabov
(D)
S Quinones Aguilar
(S)
G Quinones Canales
(G)
S Raghev
(S)
H Rickmann
(H)
M Romano
(M)
R L Rosales
(RL)
I Rubanovits
(I)
V Santilli
(V)
L Schoels
(L)
M Simonetta-Moreau
(M)
M A Simu
(MA)
Y H Sohn
(YH)
S Soulayrol
(S)
I Supe
(I)
M Svetel
(M)
T Sycha
(T)
E K Tan
(EK)
S Timerbaeva
(S)
A B Tokcaer
(AB)
R Trosch
(R)
V Tugnoli
(V)
V Tumas
(V)
C Van der Linden
(C)
A Vetra
(A)
C Vial
(C)
E Vidry
(E)
D Williams
(D)
S Wimalaratna
(S)
C Yiannikas
(C)
Commentaires et corrections
Type : ErratumIn
Références
PLoS One. 2017 Feb 7;12(2):e0170988
pubmed: 28170443
J Neurol. 2002 Jul;249(7):842-6
pubmed: 12140667
Handb Clin Neurol. 2011;100:481-511
pubmed: 21496604
Mov Disord. 2000 Jan;15(1):150-3
pubmed: 10634256
Tremor Other Hyperkinet Mov (N Y). 2013 Nov 04;3:
pubmed: 24255801
Mov Disord. 2011 Jun;26(7):1206-17
pubmed: 21484874
Neurology. 2000;55(12 Suppl 5):S2-8
pubmed: 11188980
J Neurol. 2018 Feb;265(2):402-409
pubmed: 29270685
Parkinsonism Relat Disord. 2018 Jul;52:94-97
pubmed: 29530726
Value Health. 2012 May;15(3):401-3
pubmed: 22583448
Neurotox Res. 2012 Nov;22(4):265-73
pubmed: 22359151
J Med Econ. 2012;15(3):419-23
pubmed: 22208596
Mov Disord. 1991;6(2):119-26
pubmed: 2057004
J Neurol. 2015;262(4):837-48
pubmed: 25605434
Arch Neurol. 1990 May;47(5):548-52
pubmed: 2334302
Toxins (Basel). 2013 Apr 23;5(4):776-83
pubmed: 23612751
BMJ. 2010 Jun 21;340:c2921
pubmed: 20566597
Neurology. 2016 May 10;86(19):1818-26
pubmed: 27164716
Neurol Clin. 2008 May;26 Suppl 1:23-42
pubmed: 18603166
Funct Neurol. 2012 Oct-Dec;27(4):225-30
pubmed: 23597436
Eur J Neurol. 2011 Jan;18(1):5-18
pubmed: 20482602
Neurol Res. 2009 Jun;31(5):463-6
pubmed: 19278576
Toxins (Basel). 2013 Feb 04;5(2):249-66
pubmed: 23381141
J Neurol Neurosurg Psychiatry. 2002 May;72(5):608-14
pubmed: 11971047
Eur J Neurol. 2005 Mar;12(3):163-70
pubmed: 15693803
Clin Neurol Neurosurg. 2009 Feb;111(2):161-4
pubmed: 18995953
Mov Disord. 2004 Mar;19(3):303-8
pubmed: 15022184
Complement Ther Clin Pract. 2005 Nov;11(4):262-5
pubmed: 16290897
Lancet. 1986 Aug 2;2(8501):245-7
pubmed: 2874278